Supriya Lifescience Ltd

Supriya Lifescience Q3 FY26 Update: 11% Revenue Growth, 35% Margins & ₹1,000 Cr FY27 Target 📈

• Q3 FY26 revenue: ₹206 crores, up 11% year-on-year

• EBITDA margin: 34.9%; PAT margin: 24.1% for Q3

• Exports contributed 82% of Q3 revenue (LatAm 24%, North America 6%)

• Backward integration reached 74% of revenues

• Ambernath facility ready for capitalization in Q4 FY26, targeting 2.5x capital value in revenue

• Annual revenue growth guidance: ~20%; EBITDA margin guidance: 33-35%

• FY27 revenue target: ₹1,000 crores

• Capex: ₹71 crores in 9M FY26 (mainly Ambernath) + ₹15 crores expected remainder FY26

• ATS-8 product visibility: 300 tons; commercialization scaling to 250-300 tons in FY27